Scientific Program - Wednesday 21 February

Print
Please see below the CODHy Scientific Program. Please click on the appropriate day to view the relevant program. To view the program timetable / overview, please click here

 

   
Wednesday 21 February Thursday 22 February, 2018
Wednesday 21 February, 2018
HALL A
09:00-10:30
09:00-09:05
09:00-09:30
09:30-09:55
09:55-10:20
10:20-10:30
PLENARY OPENING SESSION 1 – DIABETES TOMORROW
Chairpersons: Stefano Del Prato, Italy and Itamar Raz, Israel
Pharmacologic therapy: What’s next? Ralph DeFronzo, USA
Precision medicine: Myth or reality? Stefano Del Prato, Italy
SGLT2i's and CVD REAL, the complete story: Mikhail Kosiborod, USA
Discussion
10:30-11:00
COFFEE BREAK
HALL A
11:00-12:30
11:00-11:05
11:05-11:20
11:20-11:40
11:40-12:00
12:00-12:15
12:15-12:30
SESSION 2 – IDENTIFYING SUBJECTS AT RISK
Chairperson: Micha Rapaport, Israel and Jaako Tuomilheto, Finalnd
To screen or no to screen? Jaako Tuomilheto, Finland
Genes vs. phenotype: Valeriya Lyssenko, Sweden
Cost-effectiveness of prevention: Orly Tamir, Israel
The long-term effect of the environment – Epigenetics: Charlotte Ling, Sweden
Discussion
HALL B
11:00-12:30
11:00-11:05
11:05-11:25
11:25-11:45
11:45-12:05
12:00-12:30
SESSION 3 – TREATMENT INDIVIDUALIZATION
Chairperson: Avi Karasik, Israel and Philippe Froguel, France
Pharmacogenomics: Philippe Froguel, France
Treatment personalization after the CVO trials: Enzo Bonora, Italy
Decision support: Are we there? Avivit Cahn, Israel
Discussion
HALL C
11:00-12:30
11:00-11:05
11:05-11:25
11:25-11:45
11:45-12:05
12:00-12:30
SESSION 4 – PREVENTING DIABETIC NEPHROPATHY
Chairperson: Yoram Yagil, Israel and Ning Guang, China
Diabetic CKD: An evolving phenotype: Anna Solini, Italy
Incretins: Ning Guang, China
SGLT2-inhibitors: Ofri Mosenzen, Israel
Discussion
12:30-13:30
LUNCH
HALL A
13:30-15:00
13:30-13:35
13:35-13:55
13:55-14:15
14:15-14:35
14:35-15:00
SESSION 5 – NEW ANTI-HYPERGLYCEMIC AGENTS AND DIABETES PREVENTION
Chairperson: Mordechai Ravid, Israel and Baptist Gallwitz, Germany
DPP4-inhibitors: Baptist Gallwitz, Germany
GLP-1 RAS: Agostino Consoli, Italy
SGLT2-inhibitors: John Wilding, UK
Discussion
HALL B
13:30-15:00
13:30-13:35

13:35-14:05
14:05-14:35
14:35-15:00
SESSION 6 – TREATMENT INITIATION IN T2DM
Chairperson: Naim Shehadeh, Israel, Bracha Dagan, Israel and Jaime Davidson, USA
The role and meaning of guidelines: Jaime Davidson, USA
Treat-to-goal or pathophysiological driven treatment? Ralph DeFronzo, USA
Discussion
HALL C
13:30-15:00
13:30-13:35
13:35-14:05
14:05-14:35
14:35-15:00
SESSION 7 – THE ELDERLY T2DM
Chairperson: Evgene Merzon, Israel and Stefano Volpato, Italy
Obesity and sarcopenia: Stefano Volpato, Italy
How to select anti-hyperglycemic treatment: Antonio Ceriello, Italy
Discussion
HALL A
15:00-16:30
15:00-15:05
15:05-15:25
15:25-15:45
15:45-16:05
16:05-16:30
SESSION 8 – NEW PLAYERS IN T2DM
Chairperson: Karsten Kristiansen, Denmark and Ran Oren, Israel
NAFLD/NASH: Ran Oren, Israel
Microbioma: Karsten Kristiansen, Denmark
CVOT- what’s next? Eberhard Standl, Germany
Discussion
HALL B
15:00-16:30
15:00-15:05
15:05-15:25
15:25-15:45
15:45-16:05
16:05-16:30
SESSION 9 – WHAT TO TREAT IN T2DM
Chairperson: Baruch Itzhak, Israel and Apostolos Tsapas, Greece
The cardiologist: Chaim Lotan, Israel
The diabetologist: Apostolos Tsapas, Greece
The family physician: Xavier Cos Claramunt, Spain
Discussion
HALL C
15:00-16:30
15:00-15:05

15:05-15:20
15:20-15:35

15:35-15:50
15:50-16:05
16:05-16:30
SESSION 10 – HYPERTENSION I
Chairperson: Anna Solini, Italy
Does weight loss effective in lowering BP in the long run?
Yes: Dror Dicker, Israel
No: Ehud Grossman, Israel
Drug treatment of resistant hypertension
Antialdosterone agents: Alon Grossman, Israel
Other Strategies: Anna Solini, Italy
Discussion
16:30-17:00
COFFEE BREAK
HALL A
17:00-18:30
INDUSTRY-SPONSORED SYMPOSIUM
Reducing obesity-related complications: what can we do differently?